Antibody–drug conjugate - Wikipedia
Antibody–drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. [1] Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells. As of 2019, some 56 pharmaceutical companies were developing ADCs.
Antibody drug conjugate: the “biological missile” for ... - Nature
2022年3月22日 · Antibody–drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs) covalently attached to a cytotoxic drug via a chemical linker.
Exploring the next generation of antibody–drug conjugates
2024年1月8日 · Antibody–drug conjugates (ADCs) have emerged as a promising class of cancer therapeutics. An ADC consists of a monoclonal antibody and a potent cytotoxic payload connected through a chemical...
The Journey of Antibody-Drug Conjugates: Lessons Learned …
2024年11月1日 · Antibody-drug conjugates (ADC) represent one of the most rapidly expanding treatment modalities in oncology, with 11 ADCs approved by the FDA and more than 210 currently being tested in clinical trials.
Introduction to Antibody-Drug Conjugates - PMC - PubMed …
Antibody-drug conjugates (ADC) are antibodies (mAbs) engineered to utilize the capability of monoclonal antibodies by combining them to cytotoxic agents. An ideal ADC has the following features: A monoclonal antibody (mAb) that targets a …
A comprehensive overview on antibody-drug conjugates: from …
2023年9月18日 · Antibody-Drug Conjugates (ADCs) represent an innovative class of potent anti-cancer compounds that are widely used in the treatment of hematologic malignancies and solid tumors.
Antibody-Drug Conjugates: A Comprehensive Review - PubMed
Antibody-drug conjugates (ADC) are one of the fastest growing anticancer drugs. This approach comprises a mAb conjugated to the cytotoxic payload via a chemical linker that directed toward a target antigen expressed on the cancer cell surface, …
Rise of Antibody-Drug Conjugates: The Present and Future
2023年5月25日 · Antibody-drug conjugates (ADCs) embody a simple, but elegant, vision for cancer therapy—the delivery of a potent cytotoxic agent to tumor cells with minimal damage to normal cells—so-called smart chemo.
The antibody–drug conjugate landscape - Nature
2024年4月16日 · Antibody–drug conjugates (ADCs) have become a key therapeutic modality in oncology, spurred by superior clinical profiles compared to standard-of-care chemotherapy across multiple indications.
Antibody-Drug Conjugates: Functional Principles and …
Antibody-drug conjugates (ADCs) comprise a fast-expanding therapeutic modality designed to target disease cells, sparing the adjacent healthy tissues.